

# Caroline Houillier

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8584932/publications.pdf>

Version: 2024-02-01

28  
papers

937  
citations

567281

15  
h-index

501196

28  
g-index

28  
all docs

28  
docs citations

28  
times ranked

1107  
citing authors

#	ARTICLE	IF	CITATIONS
1	Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. <i>Lancet Haematology</i> , 2015, 2, e251-e259.	4.6	164
2	Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. <i>Neuro-Oncology</i> , 2016, 18, 1297-1303.	1.2	135
3	Management and outcome of primary CNS lymphoma in the modern era. <i>Neurology</i> , 2020, 94, e1027-e1039.	1.1	125
4	Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma. <i>Neurology</i> , 2015, 84, 325-326.	1.1	84
5	Ibrutinib monotherapy in relapsed/refractory CNS lymphoma: A retrospective case series. <i>Neurology</i> , 2017, 88, 101-102.	1.1	65
6	Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study. <i>Journal of Neuro-Oncology</i> , 2017, 133, 315-320.	2.9	47
7	Ibrutinib Monotherapy in Relapse or Refractory Primary CNS Lymphoma (PCNSL) and Primary Vitreo-Retinal Lymphoma (PVRL). Result of the Interim Analysis of the iLOC Phase II Study from the Lysa and the French LOC Network. <i>Blood</i> , 2016, 128, 784-784.	1.4	34
8	Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 3692-3698.	1.6	31
9	Primary vitreoretinal lymphomas display a remarkably restricted immunoglobulin gene repertoire. <i>Blood Advances</i> , 2020, 4, 1357-1366.	5.2	29
10	Effectiveness and tolerability of lacosamide as add-on therapy in patients with brain tumor-related epilepsy: Results from a prospective, noninterventional study in European clinical practice (VIBES). <i>Epilepsia</i> , 2020, 61, 647-656.	5.1	28
11	Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma in immunocompetent patients. <i>Haematologica</i> , 2018, 103, e296-e299.	3.5	23
12	Intravenous high-dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: An LOC network study. <i>American Journal of Hematology</i> , 2021, 96, 823-833.	4.1	18
13	Primary Oculocerebral Lymphoma: MTX Polychemotherapy Alone on Intraocular Disease Control. <i>Ophthalmology</i> , 2016, 123, 2047-2050.	5.2	17
14	Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma. <i>Neurology</i> , 2019, 93, e1799-e1806.	1.1	17
15	Temozolomide is effective and well tolerated in patients with primary vitreoretinal lymphoma. <i>Blood</i> , 2020, 135, 1811-1815.	1.4	17
16	Prognostic value of early 18F-FDG PET scanning evaluation in immunocompetent primary CNS lymphoma patients. <i>Oncotarget</i> , 2018, 9, 16822-16831.	1.8	17
17	Pretreatment Hemoglobin as an Independent Prognostic Factor in Primary Central Nervous System Lymphomas. <i>Oncologist</i> , 2019, 24, e898-e904.	3.7	16
18	A genome-wide association study identifies susceptibility loci for primary central nervous system lymphoma at 6p25.3 and 3p22.1: a LOC Network study. <i>Neuro-Oncology</i> , 2019, 21, 1039-1048.	1.2	13

#	ARTICLE	IF	CITATIONS
19	Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life: experience of the French Network. Bone Marrow Transplantation, 2022, 57, 966-974.	2.4	12
20	Optimization of CSF biological investigations for CNS lymphoma diagnosis. American Journal of Hematology, 2019, 94, 1123-1131.	4.1	9
21	Primary vitreoretinal lymphoma: short review of the literature, results of a European survey and French guidelines of the LOC network for diagnosis, treatment and follow-up. Current Opinion in Oncology, 2021, 33, 420-431.	2.4	8
22	Cerebrospinal fluid interleukin (IL)-10 and IL-10:IL-6 ratio as biomarkers for small B-cell lymphoproliferations with leptomeningeal dissemination. Seminars in Hematology, 2018, 55, 179-181.	3.4	7
23	Primary Central Nervous System Lymphoma in Elderly Patients: Management and Perspectives. Cancers, 2021, 13, 3479.	3.7	6
24	Very High Efficiency of ICE (Ifosfamide-Carboplatin-Etoposide) in Relapse/Refractory (R/R) Primary Central Nervous System (PCNSL) and Vitreo-Retinal (VRL) Non Hodgkin Lymphoma. a LOC Network Multicenter Retrospective Study on 58 Cases. Blood, 2015, 126, 1524-1524.	1.4	6
25	Clinical features and outcome of patients with primary central nervous system lymphoma admitted to the intensive care unit: a French national expert center experience. Journal of Neurology, 2021, 268, 2141-2150.	3.6	4
26	Treatment of Primary Central Nervous System Lymphoma in Immunocompetent Patients. Current Treatment Options in Neurology, 2019, 21, 39.	1.8	2
27	Isolated intraocular relapses of primary cerebral lymphomas: An LOC network study. Hematological Oncology, 2022, 40, 976-986.	1.7	2
28	Treating central nervous system lymphoma in the era of precision medicine. Expert Review of Precision Medicine and Drug Development, 2020, 5, 275-281.	0.7	1